Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma

Abstract

Inflammatory breast carcinoma (IBC) is characterized by florid tumor emboli within lymphovascular spaces termed lymphovascular invasion (LVI). Using a human-scid model of IBC (MARY-X), we have demonstrated using retrovirally-mediated dominant-negative E-cadherin mutant approaches (H-2Kd-E-cad), that the tumor cell embolus (IBC spheroid) forms on the basis of an intact and overexpressed E-cadherin/α, β-catenin axis which mediates tumor cell–tumor cell adhesion analogous to the embryonic blastocyst and accounts for the compactness of the embolus. The tumor cell embolus (IBC spheroid), in contrast, fails to bind the surrounding vascular endothelial cells both in vitro and in vivo because of markedly decreased sialyl-Lewis X/A carbohydrate ligand-binding epitopes on its overexpressed MUC1 which are necessary for binding endothelial cell E-selectin. This tumor cell-endothelial cell aversion further contributes to the compactness of the IBC spheroid and its passivity in metastasis dissemination. This passivity is manifested by a dramatic increase in metastatic pulmonary emboli following palpation of the primary tumor. In assessing this passivity of metastatic dissemination, we compared the effects of palpation on MARY-X with the effects of palpation on a derived dominant-negative E-cadherin mutant (H-2Kd-E-cad), as well as other well known human tumoral xenografts exhibiting no (MCF-7, T47D), low (MDA-MB-231, MDA-MB-468) or high (C8161, M24met) levels of spontaneous metastasis but no LVI. Palpation of each xenograft similarly increased intratumoral pressure by 200% (10→30 mmHg) but dramatically increased the numbers and sizes of pulmonary metastases 10–100-fold (P<0.001) only in MARY-X. The mechanism of this effect was through an immediate post-palpation release of circulating tumor emboli detected 2–3 min after palpation (P<0.01) by human cytokeratin 19 RT–PCR of extracted RNA from 300 μl of murine blood. Although circulating human tumor cell–derived growth factors (IGF-I, IGF-II, TGF-α and TGF-β) and angiogenic factors (VEGF and bFGF) were detected by ELISA in murine serum of MARY-X, palpation did not further increase the circulating levels of these factors (P>0.1). Our findings support the cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in IBC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ . 2000 Nature Med. 6: 100–102

  • Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH . 1999 Cancer Res. 59: 5079–5084

  • Barsky SH, Sternlicht M, Safarians S, Nguyen M, Chin K, Stewart SD, Hiti AL, Gray JW . 1997 Oncogene 15: 2077–2091

  • Battaglia M, Pedrazzoli P, Palermo B, Lanza A, Bertolini F, Gibelli N, Da Prada GA, Zambelli A, Perotti C, Robustelli della Cuna G . 1998 Bone Marrow Transplant. 22: 693–698

  • Bischoff J, Brasel C . 1995 Biochem. Biophys. Res. Commun. 210: 174–180

  • Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DSB . 1998 J. Clin. Oncol. 16: 2632–2640

  • Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA . 1993 Cancer Res. 53: 4129–4133

  • Gumbiner BM . 1996 Cell 84: 345–357

  • Kansas GS . 1996 Blood 88: 3259–3287

  • Kleer CG, van Golen KL, Braun T, Merajver SD . 2001 Mod. Pathol. 14: 458–464

  • Kruger W, Krzizanowski C, Holweg M, Stockshlader M, Kroger N, Jung R, Mross K, Jonat W, Zander AR . 1996 J. Cancer Res. Clin. Oncol. 122: 679–686

  • Levine PH, Steinhorn SC, Ries LG, Aron JL . 1985 J. Natl. Cancer Inst. 74: 291–297

  • Liotta LA, Kleinerman J, Saidel GM . 1976 Cancer Res. 36: 889–894

  • Liotta LA, Steeg PS, Stetler-Stevenson WG . 1991 Cell 64: 327–336

  • Moore DH, Rouse MB, Massenburg GS, Zeman EM . 1992 Gynecol. Oncol. 47: 44–47

  • Mori M, Mimori K, Ueo H, Karimine N, Barnard GF, Sugimachi K, Akiyoshi T . 1996 Int. J. Cancer 68: 739–743

  • Naviaux RK, Costanzi E, Haas M, Verma I . 1996 J. Virol. 70: 5701–5705

  • Nguyen M, Corless CL, Kräling BM, Tran C, Atha T, Bischoff J, Barsky SH . 1997 Am. J. Pathol. 150: 1307–1314

  • Nishizaki T, Matsumato T, Kanematsu T, Yasunaga C, Sugimachi K . 1990 J. Surg. Res. 49: 92–97

  • Noun G, Reboul M, Abastado JP, Jaulin C, Kourilsky P, Pla M . 1996 J. Immunol. 157: 2455–2461

  • Rutz HP . 1999 Med. Hypoth. 53: 526–529

  • Silverstein MJ. . ed 1997 Ductal Carcinoma in Situ of the Breast Baltimore, Maryland: Williams & Wilkins

    Google Scholar 

  • Tomlinson JS, Alpaugh ML, Barsky SH . 2001 Cancer Res. 61: 5231–5241

  • Van Golen KL, Davies S, Wu ZF, Wang YF, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD . 1999 Clin Cancer Res. 5: 2511–2519

  • Van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD . 2000 Cancer Res. 60: 5832–5838

  • Wong IH-N, Leung T, Ho S, Lau WY, Chan M, Johnson PJ . 1997 Br J. Cancer 76: 628–633

  • Wyld DK, Selby P, Perren TJ, Jonas SK, Allen-Mersh TG, Wheeldon J, Burchill SA . 1998 Int. J. Cancer 79: 288–293

  • Yap AS, Brieher WM, Gumbiner BM . 1997 Annu. Rev. Cell. Dev Biol. 13: 119–146

  • Zhu AJ, Watt FM . 1996 J. Cell Science 109: 3013–3023

Download references

Acknowledgements

This work was supported by grant CA BCRP 5JB-0104 from the California Breast Cancer Research Program and grant 99-003173 from the Susan G Komen Breast Cancer Foundation. ML Alpaugh and JS Tomlinson contributed equally to this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sanford H Barsky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alpaugh, M., Tomlinson, J., Kasraeian, S. et al. Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma. Oncogene 21, 3631–3643 (2002). https://doi.org/10.1038/sj.onc.1205389

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205389

Keywords

This article is cited by

Search

Quick links